

INVESTOR WEBINAR | SEPTEMBER 19, 2023

“XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs”

SPEAKER BIOS



Sanjay J. Mathew, MD, is the Marjorie Bintliff Johnson and Raleigh White Johnson Jr. Vice Chair for Research and a Professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine. He is also an active clinician. His research program focuses on experimental therapeutics and pathophysiology related to treatment-resistant mood and anxiety disorders and PTSD, with a particular focus on rapid-acting and novel pharmacotherapies.

Dr. Mathew graduated from Dartmouth College and Baylor College of Medicine. He then trained in psychiatry and mood/anxiety disorders research at Columbia University and the New York State Psychiatric Institute. Prior to his current position at Baylor College of Medicine, he served as faculty at the Icahn School of Medicine at Mount Sinai, where he co-directed the Mood & Anxiety Disorders Program. Dr. Mathew has authored and co-authored over 180 manuscripts and book chapters, serving on the editorial board of several journals. In 2016, he co-edited the book, *Ketamine for Treatment-Resistant Depression*. He's on the boards of the American Society of Clinical Psychopharmacology and the Anxiety and Depression Association of America, where he serves as the chief medical officer. He is also an elected fellow of the American College of Neuropsychopharmacology.



James W. Murrough, MD, PhD is Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. He is a faculty member of the Friedman Brain Institute and a Primary Principal Investigator of the Center of Excellence in Neuropharmacology, both components of the Icahn School of Medicine. Dr. Murrough conducts clinical and translational research aimed at

understanding the biological basis of mood and anxiety disorders in order to point the way towards new, more effective treatments. He received his Bachelor of Science in Neuroscience and Behavioral Biology from Emory University in Atlanta and his Medical degree from Tufts University School of Medicine in Boston. He completed his residency training in Psychiatry at Mount Sinai and a research fellowship in experimental therapeutics and clinical neuroscience in mood disorders, also at Mount Sinai. He obtained a PhD in clinical research methodology and biostatistics from Mount Sinai as part of a Career Development Award from the National Institute of Mental Health. Dr. Murrough has received research support from the National Institutes of Health, the Doris Duke Charitable Foundation, the American Foundation for Suicide Prevention, the Dana Foundation and the Brain and Behavior Research Foundation. He is a Member of the American College of Neuropsychopharmacology and an active member of the scientific community. In addition to his research and educational activities, Dr. Murrough maintains an active clinical practice focusing on evidence-based pharmacological treatments for mood and anxiety disorders.